Comparison of Charlson Comorbidity Index and Modified 5-Factor Frailty Index as Clinical Risk Stratification Tools in Predicting Adverse Outcomes in Patients Undergoing Lower Extremity Free-Flap Reconstruction. Huffman SS, et al, J Reconstr Microsurg 2023.
- Proposé le : 08/04/2024 04:07:10
- Par : Bot
- Avec la version du site : v2021_01_12
- Revu par :
- Mettre votre nom d'utilisateur
- Mettre votre nom d'utilisateur
Résumé et points clés
Methods: A retrospective review of patients aged 60 years or older who underwent LE FTT reconstruction from 2011 to 2022 was performed. Comorbidity burden was measured by two validated risk-stratification tools: mFI-5 and CCI. Primary outcomes included prolonged postoperative length of stay (LOS), defined as greater than 75th percentile of the cohort, postoperative complications, and eventual amputation.
Results: A total of 115 patients were identified. Median CCI and mFI-5 were 5 (interquartile range [IQR]: 4-6) and 2 (IQR: 1-3), respectively. Average postoperative LOS was 16.4 days. Twenty-nine patients (25.2%) experienced a postoperative complication, and eight patients (7%) required LE amputation at a mean follow-up of 19.8 months. Overall, flap success was 96.5% (n = 111), and limb salvage rate was 93% (n = 108). Increased CCI was found to be independently predictive of only eventual amputation (odds ratio: 1.59; p = 0.039), while mFI-5 was not predictive of prolonged postoperative LOS, flap complications, or eventual amputation.
Conclusion: This is the first study to compare the utility of mFI-5 and CCI in predicting adverse outcomes in elderly patients undergoing LE FTT reconstruction. Our results demonstrate CCI to be a superior predictor of secondary amputation in this patient population and mFI-5 to have limited utility. Further investigation in a prospective multicenter cohort is warranted.
Références de l'article
Discussion
- Cette section peut être éditée par les relecteurs, les rédacteurs, les modérateurs et les administrateurs. Elle regroupe l'ensemble des échanges autours de la référence ci-dessus présentée.
- Référez-vous à cette page pour connaître le rôle des utilisateurs et pour participer à la discussion.
- Il n'y a, pour l'instant, aucune discussion en cours.